Masanori Toyoda
Kobe, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).
Journal: Journal of hepato-biliary-pancreatic sciences
Published: March 23, 2022
Microsatellite instability-high colorectal cancer patient-derived xenograft models for cancer immunity research.
Journal: Journal of cancer research and therapeutics
Published: December 17, 2021
Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge.
Journal: Molecular and clinical oncology
Published: October 15, 2021
Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial.
Journal: International journal of hematology
Published: October 07, 2021
Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells.
Journal: Journal of cancer research and therapeutics
Published: September 16, 2021
Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial.
Journal: Medical oncology (Northwood, London, England)
Published: August 17, 2021
A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors.
Journal: Asia-Pacific journal of clinical oncology
Published: August 07, 2021
Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.
Journal: Internal medicine (Tokyo, Japan)
Published: May 17, 2021
Incidence of venous thromboembolism in patients with solid cancers in Japan: retrospective study of 2735 patients.
Journal: International journal of hematology
Published: March 30, 2021
Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events.
Journal: Anticancer research
Published: December 13, 2020
Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
Journal: Frontiers in oncology
Published: December 05, 2020
Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial).
Journal: Cancer chemotherapy and pharmacology
Published: July 28, 2020
Last Updated: 09/26/2026